A single intrathecal dose of adenosine 2A receptor (A 2A R) agonist was previously reported to produce a multi-week reversal of allodynia in a chronic constriction injury (CCI) model of neuropathic pain. We aimed to determine if this long-term reversal was induced by A 2A R agonism versus more generalized across adenosine receptor subtypes, and begin to explore the intracellular signaling cascades involved. In addition, we sought to identify whether the enduring effect could be extended to other models of neuropathic pain. We tested an A 1 R and A 2B R agonist in CCI and found the same long duration effect with A 2B R but not A 1 R agonism. An A 2A R agonist (ATL313) produced a significant long-duration reversal of mechanical allodynia induced by long established CCI (administered 6 weeks after surgery), spinal nerve ligation and sciatic inflammatory neuropathy. To determine if ATL313 had a direct effect on glia, ATL313 was coadministered with lipopolysaccharide to neonatal microglia and astrocytes in vitro. ATL313 significantly attenuated TNFa production in both microglia and astrocytes but had no effect on LPS induced IL-10. Protein kinase C significantly reversed the ATL313 effects on TNFa in vitro in microglia and astrocytes, while a protein kinase A inhibitor only effected microglia. Both intrathecal PKA and PKC inhibitors significantly reversed the effect of the A 2A R agonist on neuropathic allodynia. Therefore, A 2A R agonists administered IT remain an exciting novel target for the treatment of neuropathic pain.
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Introduction
Neuropathic pain affects approximately 4% of the global population (Global Industry Analysts, 2011). Neuropathic pain remains intractable to available therapeutics as most available treatments target neurons (Global Industry Analysts, 2011). Glially-driven spinal neuroinflammation has received increasing attention as importantly contributing to such pain (Scholz and Woolf, 2007) . Activated microglia and astrocytes release neuroexcitatory mediators such as pro-inflammatory cytokines and chemokines (Watkins et al., 2007) . This contribution of glia in developing and maintaining neuropathic pain has led to the search for clinically relevant approaches to suppress glially-driven pain amplification.
There are four adenosine receptor subtypes, A 1 and A 3 receptors decrease cAMP, while A 2A and A 2B receptors increase cAMP (Fredholm et al., 2007) . Adenosine receptors are found on all cell types within the CNS including neurons and glia (Dare et al., 2007) .
A 2A R agonists recently attracted attention as potential glial inhibitors, based on their anti-inflammatory effects in peripheral immune cells. Remarkably, when A 2A R agonists were administered intrathecally (IT), a fascinating phenomenon was revealed; namely, a single intrathecal (IT) injection of A 2A R-selective agonists reversed neuropathic pain (mechanical allodynia, thermal hyperalgesia) for more than 4 weeks in a classic animal model of neuropathic pain, the sciatic chronic constriction injury (CCI) (Loram et al., 2009) . While many drugs briefly suppress neuropathic pain, none other induces such enduring pain inhibition. Intriguingly, we demonstrated that A 2A R agonism accounts for reversal of neuropathic pain initially, but continued A 2A R activation cannot account for the enduring reversal (Loram et al., 2009) . How a brief exposure to an A 2A R agonist creates a strikingly persistent inhibition of neuropathic pain remains unknown.
Therefore, the aim of this study was to further explore the underlying mechanism for the remarkable long-acting effect of the A 2A R agonist. We investigated whether the effects were unique to CCI, or if the long duration effect could be generalized to multiple neuropathic pain models. We further explored whether the effects were generalizable to other adenosine receptors. Our hypothesis, based on our previous findings, was that long-term
